A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized
medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide
(NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure
with preserved ejection fraction (HFpEF).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Angiotensin II Type 1 Receptor Blockers Angiotensin-Converting Enzyme Inhibitors Enalapril Enalaprilat LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan